Efficacy and Safety of Glycopyrronium/formoterol Fumarate Dihydrate Metered Dose Inhaler (gff Mdi) Delivered Using Co‐suspension Delivery Technology in Chinese Patients with Copd

EFFICACY AND SAFETY OF GLYCOPYRRONIUM/ FORMOTEROL FUMARATE DIHYDRATE METERED DOSE INHALER (GFF MDI) DELIVERED USING CO-SUSPENSION DELIVERY TECHNOLOGY IN CHINESE PATIENTS WITH COPD NANSHAN ZHONG, RONGCHANG CHEN, HAO-YAN WANG, LI ZHAO, XIAODONG MEI, ZHIQIANG QIN, PRYSELEY N. ASSAM, ANDREA MAES, UBALDO J. MARTIN,COLIN REISNER Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Diseases, National Clinical Research Centre for Respiratory Diseases, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, Beijing Friendship Hospital (Beijing Soviet Red Cross Hospital), Xichen District, Beijing, China, Shengjing Hospital of China Medical University, Heping District, Shenyang, Liaoning, China, Anhui Provincial Hospital, Hefei, Anhui, China, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning City, Guangxi Zhuang Autonomous Region, China, AstraZeneca, Shanghai, China, Pearl – a member of the AstraZeneca Group, Morristown, NJ, United States, AstraZeneca, Gaithersburg, MD, United States, and Pearl – a member of the AstraZeneca Group and AstraZeneca, Morristown, NJ, United States